Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma

What is the purpose of this trial?

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Cartesian Therapeutics, Inc.

Start Date: 01/16/2019

End Date: 02/26/2019

Last Updated: 01/17/2019

Study HIC#: 2000023653

Get Involved

For more information about this study, contact:
Laura Leary

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image


Iris Isufi

Principal Investigator